Systemic Immunotherapy Transforms Advanced Cutaneous Squamous Cell Carcinoma Management: Mechanistic Insights Guide Agent Selection
核心洞察
FDA approval of three immune checkpoint inhibitors has fundamentally transformed advanced CSCC management, enabling multidisciplinary co-management between dermatologists, Mohs surgeons, and medical oncologists.
PD-1 (搜索) inhibitors (cemiplimab, pembrolizumab) and the PD-L1 (搜索) inhibitor cosibelimab restore T-cell activation through distinct mechanisms, with cosibelimab additionally engaging innate immunity via natural killer cell activation.
Cosibelimab uniquely preserves PD-L2 (搜索) signaling, which may reduce immune-mediated adverse events compared with PD-1 (搜索) inhibition, a consideration for patients at higher toxicity risk.
The FDA approval of three immune checkpoint inhibitors has fundamentally reshaped the therapeutic landscape for advanced cutaneous squamous cell carcinoma (搜索) (CSCC), a disease once managed with limited options including EGFR inhibitors, targeted therapies, and platinum-based chemotherapy that yielded only modest outcomes. This paradigm shift now enables multidisciplinary co-management, with dermatologists and Mohs surgeons actively partnering with medical oncologists through staging, imaging, and ongoing follow-up alongside systemic therapy.
The Immunotherapy Rationale in CSCC
The high tumor mutation burden driven by cumulative UV exposure underpins CSCC's robust responsiveness to immunotherapy. Dr. Zager contrasts immunotherapy's durable responses with the shorter-lived and more toxic profile of chemotherapy, a distinction of particular importance given the elderly population that commonly presents with this disease. Unlike chemotherapy, checkpoint inhibitors offer the potential for sustained disease control with a more favorable toxicity profile.
Mechanistic Distinctions: PD-1 (搜索) Versus PD-L1 (搜索) Inhibition
Dr. Zeitouni explains that PD-1 (搜索) inhibitors such as cemiplimab and pembrolizumab bind to the PD-1 receptor on T cells, preventing the interaction between tumor-expressed PD-L1 (搜索) and T-cell PD-1, thereby restoring T-cell activation through the adaptive immune system. Cosibelimab, an anti-PD-L1 agent, binds PD-L1 on tumor cells and similarly prevents this inhibitory interaction, also restoring adaptive immune T-cell function.
Cosibelimab, however, possesses a multifaceted mechanism that extends beyond PD-1 (搜索) blockade. By binding PD-L1 (搜索), it relieves inhibition of antigen-presenting cells, enhancing their interaction with T cells. Furthermore, through its Fc domain, cosibelimab can bind and activate natural killer cells, triggering antibody-dependent cellular cytotoxicity via release of cytotoxic granules. This dual engagement of both the adaptive and innate immune systems distinguishes cosibelimab mechanistically from PD-1 inhibitors.
PD-L2 (搜索) Preservation and Toxicity Considerations
A key differentiating feature of cosibelimab is its preservation of PD-L2 (搜索) signaling. Dr. Hamid emphasizes that PD-L2 is expressed in stress-related tissue-protective contexts, and preserving its signaling — a function lost with PD-1 (搜索) inhibition — may have practical implications for patients at higher toxicity risk. This mechanistic distinction could meaningfully inform agent selection for specific patient profiles, although Dr. Hamid notes that no head-to-head comparisons between these agents currently exist.
The relevance of this distinction is amplified by the gap between clinical trial populations and real-world patients. Clinical trials tend to enroll predominantly ECOG 0 to 1 patients, whereas everyday practice frequently includes ECOG 2 patients with greater comorbidity burdens. Real-world data will therefore be essential in clarifying how these mechanistic differences translate into clinical outcomes across diverse patient populations.
When to Consider Systemic Therapy
Dr. Sondak discusses the clinical features that prompt consideration of systemic therapy in patients with recurrent, advanced, or metastatic CSCC. No single factor — such as size, histology, or location — defines unresectability. Rather, the decision rests on a combination of surgical feasibility and patient goals. Red flags include signs of major nerve involvement, regional nodal spread, and tumors where surgery would result in significant morbidity. While almost any tumor can technically be removed, the morbidity of radical surgery must be carefully weighed against the availability of effective systemic alternatives.
The integration of checkpoint inhibitors into the CSCC treatment armamentarium represents a significant advance, offering durable responses through distinct immunologic mechanisms. As real-world experience accumulates, the nuanced differences between PD-1 (搜索) and PD-L1 (搜索) inhibition may increasingly guide personalized treatment decisions for this challenging disease.